Big pharma, Partnering, Pharma

Zai licenses Brivanib from BMS

Posted on 24 March 2015

Tags: , ,

Bristol-Myers Squibb and ZAI Lab have signed a definitive agreement under which ZAI Lab will acquire exclusive rights in China (including Hong Kong and Macau) to develop, manufacture and commercialize brivanib, an orally available kinase inhibitor in Phase 3 development for oncology indications including hepatocellular carcinoma (HCC).

ZAI Lab will be responsible for developing, manufacturing and commercializing brivanib in China.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time


Bristol-Myers Squibb will be eligible to receive development based milestone payments and tiered royalties from the commercial sales of brivanib in China, if brivanib is approved for marketing by Chinese authorities.

Bristol-Myers Squibb also will have the option to co-promote brivanib in China with ZAI Lab and share commercial profits.

Bristol-Myers Squibb retains all development and commercialization rights to brivanib outside of China, Macau and Hong Kong.

Additional terms were not disclosed.

For further deal information visit Current Agreements (subscription required)


Scorecard: Top partnering deals by value in 2015

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply